{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:24:00Z","timestamp":1782955440674,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson&apos;s Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008440","name":"International Parkinson and Movement Disorder Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson&apos;s Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 EY033438"],"award-info":[{"award-number":["K23 EY033438"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS099129"],"award-info":[{"award-number":["R01 NS099129"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.parkreldis.2022.08.013","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T09:44:59Z","timestamp":1660902299000},"page":"17-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Atypical antipsychotic use and mortality risk in Parkinson disease"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-764X","authenticated-orcid":false,"given":"Thanh Phuong","family":"Pham Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali G.","family":"Hamedani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-7168","authenticated-orcid":false,"given":"Daniel","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison W.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.parkreldis.2022.08.013_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaneurol.2016.0031","article-title":"Association of antipsychotic use with mortality risk in patients with Parkinson disease","volume":"73","author":"Weintraub","year":"2016","journal-title":"JAMA Neurol."},{"issue":"109","key":"10.1016\/j.parkreldis.2022.08.013_bib2","first-page":"266","article-title":"Treatment of Parkinson's disease psychosis","volume":"27","author":"Black","year":"2017","journal-title":"Med. Int. Rev."},{"issue":"12","key":"10.1016\/j.parkreldis.2022.08.013_bib3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40266-016-0416-8","article-title":"Psychosis in Parkinson disease: a review of etiology, phenomenology, and management","volume":"33","author":"Samudra","year":"2016","journal-title":"Drugs Aging"},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.013_bib4","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s13311-020-00875-w","article-title":"Management of psychiatric disorders in Parkinson's disease : neurotherapeutics - movement disorders therapeutics","volume":"17","author":"Weintraub","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.parkreldis.2022.08.013_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.9740\/mhc.2017.11.262","article-title":"Treatment of psychotic symptoms in patients with Parkinson disease","volume":"7","author":"Chen","year":"2017","journal-title":"Ment. Health Clin."},{"issue":"8","key":"10.1016\/j.parkreldis.2022.08.013_bib6","first-page":"27","article-title":"Psychotropic side effects of commonly prescribed medications in the elderly","volume":"11","author":"Desai","year":"2004","journal-title":"Prim. Psychiatr."},{"issue":"9","key":"10.1016\/j.parkreldis.2022.08.013_bib7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200326090-00004","article-title":"Treatment of psychosis in Parkinson's disease: safety considerations","volume":"26","author":"Fernandez","year":"2003","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.013_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/jnnp.2008.152579","article-title":"When a Parkinson's disease patient starts to hallucinate","volume":"8","author":"Poewe","year":"2008","journal-title":"Practical Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.08.013_bib9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1176\/appi.ajp.2008.08020294","article-title":"Psychosis in the elderly","volume":"166","author":"Kyomen","year":"2009","journal-title":"Am. J. Psychiatr."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.08.013_bib10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.013_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41467-017-00716-z","article-title":"Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors","volume":"8","author":"Sykes","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.parkreldis.2022.08.013_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","article-title":"Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences","volume":"192","author":"Aringhieri","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.parkreldis.2022.08.013_bib13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","article-title":"Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis","volume":"33","author":"Lako","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.parkreldis.2022.08.013_bib14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14656566.2018.1445721","article-title":"Pharmacological interventions for psychosis in Parkinson's disease patients","volume":"19","author":"Friedman","year":"2018","journal-title":"Expet Opin. Pharmacother."},{"issue":"5","key":"10.1016\/j.parkreldis.2022.08.013_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatr."},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.013_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/11319120-000000000-00000","article-title":"Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review","volume":"33","author":"Sacchetti","year":"2010","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.parkreldis.2022.08.013_bib17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/archinte.165.6.696","article-title":"Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest","volume":"165","author":"Liperoti","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.parkreldis.2022.08.013_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jpsychires.2019.07.005","article-title":"Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease","volume":"117","author":"Chekani","year":"2019","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.013_bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatr."},{"issue":"9916","key":"10.1016\/j.parkreldis.2022.08.013_bib20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.parkreldis.2022.08.013_bib21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1212\/WNL.0000000000006396","article-title":"Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine","volume":"91","author":"Moreno","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.parkreldis.2022.08.013_bib22","first-page":"785","article-title":"Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis","volume":"27","author":"Brown","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"13","key":"10.1016\/j.parkreldis.2022.08.013_bib23","doi-asserted-by":"crossref","first-page":"e1266","DOI":"10.1212\/WNL.0000000000012601","article-title":"Risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson disease","volume":"97","author":"Hwang","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.013_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr. Epidemiol. Rep."},{"issue":"9","key":"10.1016\/j.parkreldis.2022.08.013_bib25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.parkreldis.2022.08.013_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110531","article-title":"Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury","volume":"130","author":"Leonard","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.parkreldis.2022.08.013_bib27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/phar.2457","article-title":"Impact of hospitalization and medication switching on post-discharge adherence to oral anticoagulants in patients with atrial fibrillation","volume":"40","author":"Pham Nguyen","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.parkreldis.2022.08.013_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jagp.2021.07.018","article-title":"Medicare claims data underestimate hallucinations in older adults with dementia","volume":"30","author":"Hamedani","year":"2022","journal-title":"Am. J. Geriatr. Psychiatr."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.013_bib29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12883-021-02265-x","article-title":"Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?","volume":"21","author":"Pham Nguyen","year":"2021","journal-title":"BMC Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2022.08.013_bib30","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/pds.1926","article-title":"A basic study design for expedited safety signal evaluation based on electronic healthcare data","volume":"19","author":"Schneeweiss","year":"2010","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802022002693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802022002693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:27:38Z","timestamp":1778801258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802022002693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":30,"alternative-id":["S1353802022002693"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.08.013","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical antipsychotic use and mortality risk in Parkinson disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}